EXHIBIT 10.1
UNITED STATES DEPARTMENT OF THE
TREASURY
1500 PENNSYLVANIA AVENUE, NW
WASHINGTON, D.C. 20220
Dear Ladies and Gentlemen:
The company set forth on the
signature page hereto (the “ Company ”)
intends to issue in a private placement the number of shares of a
series of its preferred stock set forth on Schedule A hereto (the
“ Preferred Shares ”) and a warrant to purchase
the number of shares of its common stock set forth on Schedule A
hereto (the “ Warrant ” and, together with the
Preferred Shares, the “ Purchased Securities ”)
and the United States Department of the Treasury (the “
Investor ”) intends to purchase from the Company the
Purchased Securities.
The purpose of this letter agreement
is to confirm the terms and conditions of the purchase by the
Investor of the Purchased Securities. Except to the extent
supplemented or superseded by the terms set forth herein or in the
Schedules hereto, the provisions contained in the Securities
Purchase Agreement – Standard Terms attached hereto as
Exhibit A (the “ Securities Purchase Agreement
”) are incorporated by reference herein. Terms that are
defined in the Securities Purchase Agreement are used in this
letter agreement as so defined. In the event of any
inconsistency between this letter agreement and the Securities
Purchase Agreement, the terms of this letter agreement shall
govern.
Each of the Company and the Investor
hereby confirms its agreement with the other party with respect to
the issuance by the Company of the Purchased Securities and the
purchase by the Investor of the Purchased Securities pursuant to
this letter agreement and the Securities Purchase Agreement on the
terms specified on Schedule A hereto.
This letter agreement (including the
Schedules hereto) and the Securities Purchase Agreement (including
the Annexes thereto) and the Warrant constitute the entire
agreement, and supersede all other prior agreements,
understandings, representations and warranties, both written and
oral, between the parties, with respect to the subject matter
hereof. This letter agreement constitutes the “Letter
Agreement” referred to in the Securities Purchase
Agreement.
This letter agreement may be
executed in any number of separate counterparts, each such
counterpart being deemed to be an original instrument, and all such
counterparts will together constitute the same agreement.
Executed signature pages to this letter agreement may be
delivered by facsimile and such facsimiles will be deemed as
sufficient as if actual signature pages had been
delivered.
* * *
In witness whereof, this letter
agreement has been duly executed and delivered by the duly
authorized representatives of the parties hereto as of the date
written below.
|
|
UNITED STATES DEPARTMENT OF THE
TREASURY
|
|
|
|
|
|
|
|
|
By:
|
/s/ Neil Kashkari
|
|
|
|
Name: Neil Kashkari
|
|
|
|
Title: Interim Assistant Secretary
for Financial Stability
|
|
|
|
|
|
|
|
|
SCBT FINANCIAL CORPORATION
|
|
|
|
|
|
|
|
|
By:
|
/s/ Robert R. Hill, Jr.
|
|
|
|
Name: Robert R. Hill, Jr.
|
|
|
|
Title: President and Chief Executive
Officer
|
|
|
|
|
|
|
|
|
|
Date:
|
January 16, 2009
|
|
|
|
|
|
|
|
|
|
EXHIBIT A
SECURITIES PURCHASE
AGREEMENT
STANDARD TERMS
TABLE OF CONTENTS
|
|
|
Page
|
|
|
|
Article I
|
|
|
|
Purchase; Closing
|
|
|
|
1.1
|
Purchase
|
2
|
|
1.2
|
Closing
|
2
|
|
1.3
|
Interpretation
|
4
|
|
Article II
|
|
|
|
Representations and Warranties
|
|
|
|
2.1
|
Disclosure
|
4
|
|
2.2
|
Representations and Warranties of
the Company
|
5
|
|
|
|
|
|
Article III
|
|
|
|
Covenants
|
|
|
|
3.1
|
Commercially Reasonable
Efforts
|
15
|
|
3.2
|
Expenses
|
16
|
|
3.3
|
Sufficiency of Authorized Common
Stock; Exchange Listing
|
16
|
|
3.4
|
Certain Notifications Until
Closing
|
16
|
|
3.5
|
Access, Information and
Confidentiality
|
17
|
|
|
|
|
|
Article IV
|
|
|
|
Additional Agreements
|
|
|
|
4.1
|
Purchase for Investment
|
18
|
|
4.2
|
Legends
|
18
|
|
4.3
|
Certain Transactions
|
20
|
|
4.4
|
Transfer of Purchased Securities and
Warrant Shares; Restrictions on Exercise of the Warrant
|
20
|
|
4.5
|
Registration Rights
|
20
|
|
4.6
|
Voting of Warrant Shares
|
33
|
|
4.7
|
Depositary Shares
|
33
|
|
4.8
|
Restriction on Dividends and
Repurchases
|
33
|
|
4.9
|
Repurchase of Investor
Securities
|
34
|
|
4.10
|
Executive Compensation
|
34
|
|
4.11
|
Bank and Thrift Holding Company
Status
|
34
|
|
4.12
|
Predominantly Financial
|
36
|
i
|
Article V
|
|
|
|
Miscellaneous
|
|
|
|
5.1
|
Termination
|
36
|
|
5.2
|
Survival of Representations and
Warranties
|
37
|
|
5.3
|
Amendment
|
37
|
|
5.4
|
Waiver of Conditions
|
37
|
|
5.5
|
Governing Law: Submission to
Jurisdiction, Etc.
|
37
|
|
5.6
|
Notices
|
38
|
|
5.7
|
Definitions
|
38
|
|
5.8
|
Assignment
|
39
|
|
5.9
|
Severability
|
39
|
|
5.10
|
No Third Party
Beneficiaries
|
39
|
ii
LIST OF ANNEXES
|
ANNEX A:
|
|
FORM OF CERTIFICATE OF DESIGNATIONS FOR
PREFERRED STOCK
|
|
|
|
|
|
ANNEX B:
|
|
FORM OF WAIVER
|
|
|
|
|
|
ANNEX C:
|
|
FORM OF OPINION
|
|
|
|
|
|
ANNEX D:
|
|
FORM OF WARRANT
|
iii
INDEX OF DEFINED TERMS
|
|
|
Location of
|
|
|
Term
|
|
Definition
|
|
|
Affiliate
|
|
|
5.7(b)
|
|
|
Agreement
|
|
|
Recitals
|
|
|
Appraisal Procedure
|
|
|
4.9(c)(i)
|
|
|
Appropriate Federal Banking Agency
|
|
|
2.2(s)
|
|
|
Bank Holding Company
|
|
|
4.11
|
|
|
Bankruptcy Exceptions
|
|
|
2.2(d)
|
|
|
Benefit Plans
|
|
|
1.2(d)(iv)
|
|
|
Board of Directors
|
|
|
2.2(f)
|
|
|
Business Combination
|
|
|
4.4
|
|
|
business day
|
|
|
1.3
|
|
|
Capitalization Date
|
|
|
2.2(b)
|
|
|
Certificate of Designations
|
|
|
1.2(d)(iii)
|
|
|
Charter
|
|
|
1.2(d)(iii)
|
|
|
Closing
|
|
|
1.2(a)
|
|
|
Closing Date
|
|
|
1.2(a)
|
|
|
Code
|
|
|
2.2(n)
|
|
|
Common Stock
|
|
|
Recitals
|
|
|
Company
|
|
|
Recitals
|
|
|
Company Financial Statements
|
|
|
2.2(h)
|
|
|
Company Material Adverse Effect
|
|
|
2.1(a)
|
|
|
Company Reports
|
|
|
2.2(i)(i)
|
|
|
Company Subsidiary; Company
Subsidiaries
|
|
|
2.2(i)(i)
|
|
|
Control; Controlled By; Under Common Control
with
|
|
|
5.7(b)
|
|
|
Controlled Group
|
|
|
2.2(n)
|
|
|
CPP
|
|
|
Recitals
|
|
|
EESA
|
|
|
1.2(d)(iv)
|
|
|
ERISA
|
|
|
2.2(n)
|
|
|
Exchange Act
|
|
|
2.1(b)
|
|
|
Fair Market Value
|
|
|
4.9(c)(ii)
|
|
|
Federal Reserve
|
|
|
4.11
|
|
|
GAAP
|
|
|
2.1(a)
|
|
|
Governmental Entities
|
|
|
1.2(c)
|
|
|
Holder
|
|
|
4.5(k)(i)
|
|
|
Holders’ Counsel
|
|
|
4.5(k)(ii)
|
|
|
Indemnitee
|
|
|
4.5(g)(i)
|
|
|
Information
|
|
|
3.5(b)
|
|
|
Initial Warrant Shares
|
|
|
Recitals
|
|
|
Investor
|
|
|
Recitals
|
|
|
Junior Stock
|
|
|
4.8(c)
|
|
|
Knowledge of the Company; Company’s
knowledge
|
|
|
5.7(c)
|
|
|
Last Fiscal Year
|
|
|
2.1(b)
|
|
iv
|
|
|
Location of
|
|
|
Term
|
|
Definition
|
|
|
Letter Agreement
|
|
|
Recitals
|
|
|
officers
|
|
|
5.7(c)
|
|
|
Parity Stock
|
|
|
4.8(c)
|
|
|
Pending Underwritten Offering
|
|
|
4.5(l)
|
|
|
Permitted Repurchases
|
|
|
4.8(a)(ii)
|
|
|
Piggyback Registration
|
|
|
4.5(a)(iv)
|
|
|
Plan
|
|
|
2.2(n)
|
|
|
Preferred Shares
|
|
|
Recitals
|
|
|
Preferred Stock
|
|
|
Recitals
|
|
|
Previously Disclosed
|
|
|
2.1(b)
|
|
|
Proprietary Rights
|
|
|
2.2(u)
|
|
|
Purchase Recitals Purchase Price
|
|
|
1.1
|
|
|
Purchased Securities
|
|
|
Recitals
|
|
|
Qualified Equity Offering
|
|
|
4.4
|
|
|
register; registered; registration
|
|
|
4.5(k)(iii)
|
|
|
Registrable Securities
|
|
|
4.5(k)(iv)
|
|
|
Registration Expenses
|
|
|
4.5(k)(v)
|
|
|
Regulatory Agreement
|
|
|
2.2(s)
|
|
|
Rule 144; Rule 144A; Rule 159A;
Rule 405; Rule 415
|
|
|
4.5(k)(vi)
|
|
|
Savings and Loan Holding Company
|
|
|
4.11
|
|
|
Schedules
|
|
|
Recitals
|
|
|
SEC
|
|
|
2.1(b)
|
|
|
Securities Act
|
|
|
2.2(a)
|
|
|
Selling Expenses
|
|
|
4.5(k)(vii)
|
|
|
Senior Executive Officers
|
|
|
4.10
|
|
|
Share Dilution Amount
|
|
|
4.8(a)(ii)
|
|
|
Shelf Registration Statement
|
|
|
4.5(a)(ii)
|
|
|
Signing Date
|
|
|
2.1(a)
|
|
|
Special Registration
|
|
|
4.5(i)
|
|
|
Stockholder Proposals
|
|
|
3.1(b)
|
|
|
Subsidiary
|
|
|
5.8(a)
|
|
|
Tax; Taxes
|
|
|
2.2(o)
|
|
|
Transfer
|
|
|
4.4
|
|
|
Warrant
|
|
|
Recitals
|
|
|
Warrant Shares
|
|
|
2.2(d)
|
|
v
SECURITIES PURCHASE AGREEMENT
– STANDARD TERMS
Recitals:
WHEREAS, the United States
Department of the Treasury (the “ Investor ”)
may from time to time agree to purchase shares of preferred stock
and warrants from eligible financial institutions which elect to
participate in the Troubled Asset Relief Program Capital Purchase
Program (“ CPP ”);
WHEREAS, an eligible financial
institution electing to participate in the CPP and issue securities
to the Investor (referred to herein as the “ Company
”) shall enter into a letter agreement (the “ Letter
Agreement ”) with the Investor which incorporates this
Securities Purchase Agreement – Standard Terms;
WHEREAS, the Company agrees to
expand the flow of credit to U.S. consumers and businesses on
competitive terms to promote the sustained growth and vitality of
the U.S. economy;
WHEREAS, the Company agrees to work
diligently, under existing programs, to modify the terms of
residential mortgages as appropriate to strengthen the health of
the U.S. housing market;
WHEREAS, the Company intends to
issue in a private placement the number of shares of the series of
its Preferred Stock (“ Preferred Stock ”) set
forth on Schedule A to the Letter Agreement (the “
Preferred Shares ”) and a warrant to purchase the
number of shares of its Common Stock (“ Common Stock
”) set forth on Schedule A to the Letter Agreement
(the “ Initial Warrant Shares ”) (the “
Warrant ” and, together with the Preferred Shares, the
“ Purchased Securities ”) and the Investor
intends to purchase (the “ Purchase ”) from the
Company the Purchased Securities; and
WHEREAS, the Purchase will be
governed by this Securities Purchase Agreement – Standard
Terms and the Letter Agreement, including the schedules thereto
(the “ Schedules ”), specifying additional terms
of the Purchase. This Securities Purchase Agreement –
Standard Terms (including the Annexes hereto) and the Letter
Agreement (including the Schedules thereto) are together referred
to as this “Agreement”. All references in this
Securities Purchase Agreement – Standard Terms to
“Schedules” are to the Schedules attached to the Letter
Agreement.
NOW, THEREFORE,
in consideration of the premises,
and of the representations, warranties, covenants and agreements
set forth herein, the parties agree as follows:
1
Article I
Purchase; Closing
1.1
Purchase . On the terms and subject to the conditions set
forth in this Agreement, the Company agrees to sell to the
Investor, and the Investor agrees to purchase from the Company, at
the Closing (as hereinafter defined), the Purchased Securities for
the price set forth on Schedule A (the “ Purchase
Price ”).
1.2
Closing .
(a)
On the terms and subject to the conditions set forth in this
Agreement, the closing of the Purchase (the “ Closing
”) will take place at the location specified in Schedule
A , at the time and on the date set forth in Schedule A
or as soon as practicable thereafter, or at such other place, time
and date as shall be agreed between the Company and the Investor.
The time and date on which the Closing occurs is referred to in
this Agreement as the “ Closing Date
”.
(b)
Subject to the fulfillment or waiver of the conditions to the
Closing in this Section 1.2, at the Closing the Company will
deliver the Preferred Shares and the Warrant, in each case as
evidenced by one or more certificates dated the Closing Date and
bearing appropriate legends as hereinafter provided for, in
exchange for payment in full of the Purchase Price by wire transfer
of immediately available United States funds to a bank account
designated by the Company on Schedule A .
(c)
The respective obligations of each of the Investor and the Company
to consummate the Purchase are subject to the fulfillment (or
waiver by the Investor and the Company, as applicable) prior to the
Closing of the conditions that (i) any approvals or
authorizations of all United States and other governmental,
regulatory or judicial authorities (collectively, “
Governmental Entities ”) required for the consummation
of the Purchase shall have been obtained or made in form and
substance reasonably satisfactory to each party and shall be in
full force and effect and all waiting periods required by United
States and other applicable law, if any, shall have expired and
(ii) no provision of any applicable United States or other law
and no judgment, injunction, order or decree of any Governmental
Entity shall prohibit the purchase and sale of the Purchased
Securities as contemplated by this Agreement.
(d)
The obligation of the Investor to consummate the Purchase is also
subject to the fulfillment (or waiver by the Investor) at or prior
to the Closing of each of the following conditions:
(i)
(A) the representations and warranties of the Company set
forth in (x) Section 2.2(g) of this Agreement shall
be true and correct in all respects as though made on and as of the
Closing Date, (y) Sections 2.2(a) through (f) shall
be true and correct in all material respects as though made on and
as of the Closing Date (other than representations and warranties
that by their terms speak as of another date, which representations
and warranties shall be true and correct in all material respects
as of
2
such other date) and
(z) Sections 2.2(h) through (v) (disregarding all
qualifications or limitations set forth in such representations and
warranties as to “materiality”, “Company Material
Adverse Effect” and words of similar import) shall be true
and correct as though made on and as of the Closing Date (other
than representations and warranties that by their terms speak as of
another date, which representations and warranties shall be true
and correct as of such other date), except to the extent that the
failure of such representations and warranties referred to in this
Section 1.2(d)(i)(A)(z) to be so true and correct,
individually or in the aggregate, does not have and would not
reasonably be expected to have a Company Material Adverse Effect
and (B) the Company shall have performed in all material
respects all obligations required to be performed by it under this
Agreement at or prior to the Closing;
(ii)
the Investor shall have received a certificate signed on behalf of
the Company by a senior executive officer certifying to the effect
that the conditions set forth in Section 1.2(d)(i) have
been satisfied;
(iii)
the Company shall have duly adopted and filed with the Secretary of
State of its jurisdiction of organization or other applicable
Governmental Entity the amendment to its certificate or articles of
incorporation, articles of association, or similar organizational
document (“ Charter ”) in substantially
the form attached hereto as Annex A (the “
Certificate of Designations ”) and such filing shall
have been accepted;
(iv)
(A) the Company shall have effected such changes to its
compensation, bonus, incentive and other benefit plans,
arrangements and agreements (including golden parachute, severance
and employment agreements) (collectively, “ Benefit
Plans ”) with respect to its Senior Executive Officers
(and to the extent necessary for such changes to be legally
enforceable, each of its Senior Executive Officers shall have duly
consented in writing to such changes), as may be necessary, during
the period that the Investor owns any debt or equity securities of
the Company acquired pursuant to this Agreement or the Warrant, in
order to comply with Section 111(b) of the Emergency
Economic Stabilization Act of 2008 (“ EESA ”) as
implemented by guidance or regulation thereunder that has been
issued and is in effect as of the Closing Date, and (B) the
Investor shall have received a certificate signed on behalf of the
Company by a senior executive officer certifying to the effect that
the condition set forth in Section 1.2(d)(iv)(A) has been
satisfied;
(v)
each of the Company’s Senior Executive Officers shall have
delivered to the Investor a written waiver in the form attached
hereto as Annex B releasing the Investor from any claims
that such Senior Executive Officers may otherwise have as a result
of the issuance, on or prior to the Closing Date, of any
regulations which require the modification of, and the agreement of
the Company hereunder to modify, the terms of any Benefit Plans
with respect to its Senior Executive Officers to eliminate any
provisions of such Benefit Plans that would not be in compliance
with the requirements of Section 111(b) of the EESA as
implemented by
3
guidance or regulation thereunder
that has been issued and is in effect as of the Closing
Date;
(vi)
the Company shall have delivered to the Investor a written opinion
from counsel to the Company (which may be internal counsel),
addressed to the Investor and dated as of the Closing Date, in
substantially the form attached hereto as Annex C
;
(vii)
the Company shall have delivered certificates in proper form or,
with the prior consent of the Investor, evidence of shares in
book-entry form, evidencing the Preferred Shares to Investor or its
designee(s); and
(viii)
the Company shall have duly executed the Warrant in substantially
the form attached hereto as Annex D and delivered such
executed Warrant to the Investor or its designee(s).
1.3
Interpretation . When a reference is made in this Agreement
to “Recitals,” “Articles,”
“Sections,” or “Annexes” such reference
shall be to a Recital, Article or Section of, or Annex
to, this Securities Purchase Agreement – Standard Terms, and
a reference to “Schedules” shall be to a Schedule to
the Letter Agreement, in each case, unless otherwise
indicated. The terms defined in the singular have a
comparable meaning when used in the plural, and vice versa.
References to “herein”, “hereof”,
“hereunder” and the like refer to this Agreement as a
whole and not to any particular section or provision, unless the
context requires otherwise. The table of contents and
headings contained in this Agreement are for reference purposes
only and are not part of this Agreement. Whenever the words
“include,” “includes” or
“including” are used in this Agreement, they shall be
deemed followed by the words “without
limitation.” No rule of construction against the
draftsperson shall be applied in connection with the interpretation
or enforcement of this Agreement, as this Agreement is the product
of negotiation between sophisticated parties advised by counsel.
All references to “$” or “dollars” mean the
lawful currency of the United States of America. Except as
expressly stated in this Agreement, all references to any statute,
rule or regulation are to the statute, rule or regulation
as amended, modified, supplemented or replaced from time to time
(and, in the case of statutes, include any rules and
regulations promulgated under the statute) and to any section of
any statute, rule or regulation include any successor to the
section. References to a “ business day ” shall
mean any day except Saturday, Sunday and any day on which banking
institutions in the State of New York generally are authorized or
required by law or other governmental actions to close.
Article II
Representations and
Warranties
2.1
Disclosure .
(a)
“ Company Material Adverse Effect ” means a
material adverse effect on (i) the business, results of
operation or financial condition of the Company and its
consolidated
4
subsidiaries taken as a whole; provided ,
however , that Company Material Adverse Effect shall not be
deemed to include the effects of (A) changes after the date of
the Letter Agreement (the “ Signing Date ”) in
general business, economic or market conditions (including changes
generally in prevailing interest rates, credit availability and
liquidity, currency exchange rates and price levels or trading
volumes in the United States or foreign securities or credit
markets), or any outbreak or escalation of hostilities, declared or
undeclared acts of war or terrorism, in each case generally
affecting the industries in which the Company and its subsidiaries
operate, (B) changes or proposed changes after the Signing
Date in generally accepted accounting principles in the United
States (“ GAAP ”) or regulatory accounting
requirements, or authoritative interpretations thereof,
(C) changes or proposed changes after the Signing Date in
securities, banking and other laws of general applicability or
related policies or interpretations of Governmental Entities (in
the case of each of these clauses (A), (B) and (C), other than
changes or occurrences to the extent that such changes or
occurrences have or would reasonably be expected to have a
materially disproportionate adverse effect on the Company and its
consolidated subsidiaries taken as a whole relative to comparable
U.S. banking or financial services organizations), or
(D) changes in the market price or trading volume of the
Common Stock or any other equity, equity-related or debt securities
of the Company or its consolidated subsidiaries (it being
understood and agreed that the exception set forth in this clause
(D) does not apply to the underlying reason giving rise to or
contributing to any such change); or (ii) the ability of the
Company to consummate the Purchase and the other transactions
contemplated by this Agreement and the Warrant and perform its
obligations hereunder or thereunder on a timely basis.
(b)
“ Previously Disclosed ” means information set
forth or incorporated in the Company’s Annual Report on
Form 10-K for the most recently completed fiscal year of the
Company filed with the Securities and Exchange Commission (the
“ SEC ”) prior to the Signing Date (the “
Last Fiscal Year ”) or in its other reports and forms
filed with or furnished to the SEC under Sections 13(a), 14(a) or
15(d) of the Securities Exchange Act of 1934 (the “
Exchange Act ”) on or after the last day of the Last
Fiscal Year and prior to the Signing Date.
2.2
Representations and Warranties of the Company . Except
as Previously Disclosed, the Company represents and warrants to the
Investor that as of the Signing Date and as of the Closing Date (or
such other date specified herein):
(a)
Organization, Authority and Significant Subsidiaries .
The Company has been duly incorporated and is validly existing and
in good standing under the laws of its jurisdiction of
organization, with the necessary power and authority to own its
properties and conduct its business in all material respects as
currently conducted, and except as has not, individually or in the
aggregate, had and would not reasonably be expected to have a
Company Material Adverse Effect, has been duly qualified as a
foreign corporation for the transaction of business and is in good
standing under the laws of each other jurisdiction in which it owns
or leases properties or conducts any business so as to require such
qualification; each subsidiary of the Company that is a
“significant subsidiary” within the meaning of
Rule 1-02(w) of Regulation S-X under the Securities Act
of 1933 (the “ Securities Act ”) has been duly
organized and is validly existing in good standing under the laws
of its jurisdiction of organization. The
5
Charter and bylaws of the Company, copies of
which have been provided to the Investor prior to the Signing Date,
are true, complete and correct copies of such documents as in full
force and effect as of the Signing Date.
(b)
Capitalization . The authorized capital stock of the
Company, and the outstanding capital stock of the Company
(including securities convertible into, or exercisable or
exchangeable for, capital stock of the Company) as of the most
recent fiscal month-end preceding the Signing Date (the “
Capitalization Date ”) is set forth on Schedule
B . The outstanding shares of capital stock of the
Company have been duly authorized and are validly issued and
outstanding, fully paid and nonassessable, and subject to no
preemptive rights (and were not issued in violation of any
preemptive rights). Except as provided in the Warrant, as of the
Signing Date, the Company does not have outstanding any securities
or other obligations providing the holder the right to acquire
Common Stock that is not reserved for issuance as specified on
Schedule B , and the Company has not made any other
commitment to authorize, issue or sell any Common Stock.
Since the Capitalization Date, the Company has not issued any
shares of Common Stock, other than (i) shares issued upon the
exercise of stock options or delivered under other equity-based
awards or other convertible securities or warrants which were
issued and outstanding on the Capitalization Date and disclosed on
Schedule B and (ii) shares disclosed on Schedule
B .
(c)
Preferred Shares . The Preferred Shares have been duly and
validly authorized, and, when issued and delivered pursuant to this
Agreement, such Preferred Shares will be duly and validly issued
and fully paid and non-assessable, will not be issued in violation
of any preemptive rights, and will rank pari passu with or
senior to all other series or classes of Preferred Stock, whether
or not issued or outstanding, with respect to the payment of
dividends and the distribution of assets in the event of any
dissolution, liquidation or winding up of the Company.
(d)
The Warrant and Warrant Shares . The Warrant has been duly
authorized and, when executed and delivered as contemplated hereby,
will constitute a valid and legally binding obligation of the
Company enforceable against the Company in accordance with its
terms, except as the same may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting
the enforcement of creditors’ rights generally and general
equitable principles, regardless of whether such enforceability is
considered in a proceeding at law or in equity (“
Bankruptcy Exceptions ”). The shares of Common Stock
issuable upon exercise of the Warrant (the “ Warrant
Shares ”) have been duly authorized and reserved for
issuance upon exercise of the Warrant and when so issued in
accordance with the terms of the Warrant will be validly issued,
fully paid and non-assessable, subject, if applicable, to the
approvals of its stockholders set forth on Schedule C
.
(e)
Authorization, Enforceability .
(i)
The Company has the corporate power and authority to execute and
deliver this Agreement and the Warrant and, subject, if applicable,
to the approvals of its stockholders set forth on Schedule C
, to carry out its obligations hereunder and
6
thereunder (which includes the
issuance of the Preferred Shares, Warrant and Warrant Shares). The
execution, delivery and performance by the Company of this
Agreement and the Warrant and the consummation of the transactions
contemplated hereby and thereby have been duly authorized by all
necessary corporate action on the part of the Company and its
stockholders, and no further approval or authorization is required
on the part of the Company, subject, in each case, if applicable,
to the approvals of its stockholders set forth on Schedule C
. This Agreement is a valid and binding obligation of the Company
enforceable against the Company in accordance with its terms,
subject to the Bankruptcy Exceptions.
(ii)
The execution, delivery and performance by the Company of this
Agreement and the Warrant and the consummation of the transactions
contemplated hereby and thereby and compliance by the Company with
the provisions hereof and thereof, will not (A) violate,
conflict with, or result in a breach of any provision of, or
constitute a default (or an event which, with notice or lapse of
time or both, would constitute a default) under, or result in the
termination of, or accelerate the performance required by, or
result in a right of termination or acceleration of, or result in
the creation of, any lien, security interest, charge or encumbrance
upon any of the properties or assets of the Company or any Company
Subsidiary under any of the terms, conditions or provisions of
(i) subject, if applicable, to the approvals of the
Company’s stockholders set forth on Schedule C , its
organizational documents or (ii) any note, bond, mortgage,
indenture, deed of trust, license, lease, agreement or other
instrument or obligation to which the Company or any Company
Subsidiary is a party or by which it or any Company Subsidiary may
be bound, or to which the Company or any Company Subsidiary or any
of the properties or assets of the Company or any Company
Subsidiary may be subject, or (B) subject to compliance with
the statutes and regulations referred to in the next paragraph,
violate any statute, rule or regulation or any judgment,
ruling, order, writ, injunction or decree applicable to the Company
or any Company Subsidiary or any of their respective properties or
assets except, in the case of clauses (A)(ii) and (B), for
those occurrences that, individually or in the aggregate, have not
had and would not reasonably be expected to have a Company Material
Adverse Effect.
(iii)
Other than the filing of the Certificate of Designations with the
Secretary of State of its jurisdiction of organization or other
applicable Governmental Entity, any current report on Form 8-K
required to be filed with the SEC, such filings and approvals as
are required to be made or obtained under any state “blue
sky” laws, the filing of any proxy statement contemplated by
Section 3.1 and such as have been made or obtained, no notice
to, filing with, exemption or review by, or authorization, consent
or approval of, any Governmental Entity is required to be made or
obtained by the Company in connection with the consummation by the
Company of the Purchase except for any such notices, filings,
exemptions, reviews, authorizations, consents and approvals the
failure of which to make or obtain would not, individually or in
the aggregate, reasonably be expected to have a Company Material
Adverse Effect.
7
(f)
Anti-takeover Provisions and
Rights Plan . The Board
of Directors of the Company (the “ Board of Directors
”) has taken all necessary action to ensure that the
transactions contemplated by this Agreement and the Warrant and the
consummation of the transactions contemplated hereby and thereby,
including the exercise of the Warrant in accordance with its terms,
will be exempt from any anti-takeover or similar provisions of the
Company’s Charter and bylaws, and any other provisions of any
applicable “moratorium”, “control share”,
“fair price”, “interested stockholder” or
other anti-takeover laws and regulations of any jurisdiction.
The Company has taken all actions necessary to render any
stockholders’ rights plan of the Company inapplicable to this
Agreement and the Warrant and the consummation of the transactions
contemplated hereby and thereby, including the exercise of the
Warrant by the Investor in accordance with its terms.
(g)
No Company Material Adverse
Effect . Since the last
day of the last completed fiscal period for which the Company has
filed a Quarterly Report on Form 10-Q or an Annual Report on
Form 10-K with the SEC prior to the Signing Date, no fact,
circumstance, event, change, occurrence, condition or development
has occurred that, individually or in the aggregate, has had or
would reasonably be expected to have a Company Material Adverse
Effect.
(h)
Company Financial
Statements . Each of the
consolidated financial statements of the Company and its
consolidated subsidiaries (collectively the “ Company
Financial Statements ”) included or incorporated by
reference in the Company Reports filed with the SEC since
December 31, 2006, present fairly in all material respects the
consolidated financial position of the Company and its consolidated
subsidiaries as of the dates indicated therein (or if amended prior
to the Signing Date, as of the date of such amendment) and the
consolidated results of their operations for the periods specified
therein; and except as stated therein, such financial statements
(A) were prepared in conformity with GAAP applied on a consistent
basis (except as may be noted therein), (B) have been prepared
from, and are in accordance with, the books and records of the
Company and the Company Subsidiaries and (C) complied as to form,
as of their respective dates of filing with the SEC, in all
material respects with the applicable accounting requirements and
with the published rules and regulations of the SEC with
respect thereto.
(i)
Reports .
(i)
Since December 31, 2006, the
Company and each subsidiary of the Company (each a “
Company Subsidiary ” and, collectively, the “
Company Subsidiaries ”) has timely filed all reports,
registrations, documents, filings, statements and submissions,
together with any amendments thereto, that it was required to file
with any Governmental Entity (the foregoing, collectively, the
“ Company Reports ”) and has paid all fees and
assessments due and payable in connection therewith, except, in
each case, as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.
As of their respective dates of filing, the Company Reports
complied in all material respects with all statutes and applicable
rules and regulations of the
8
applicable Governmental
Entities. In the case of each such Company Report filed with
or furnished to the SEC, such Company Report (A) did not, as
of its date or if amended prior to the Signing Date, as of the date
of such amendment, contain an untrue statement of a material fact
or omit to state a material fact necessary in order to make the
statements made therein, in light of the circumstances under which
they were made, not misleading, and (B) complied as to form in all
material respects with the applicable requirements of the
Securities Act and the Exchange Act. With respect to all
other Company Reports, the Company Reports were complete and
accurate in all material respects as of their respective
dates. No executive officer of the Company or any Company
Subsidiary has failed in any respect to make the certifications
required of him or her under Section 302 or 906 of the
Sarbanes-Oxley Act of 2002.
(ii)
The records, systems, controls, data
and information of the Company and the Company Subsidiaries are
recorded, stored, maintained and operated under means (including
any electronic, mechanical or photographic process, whether
computerized or not) that are under the exclusive ownership and
direct control of the Company or the Company Subsidiaries or their
accountants (including all means of access thereto and therefrom),
except for any non-exclusive ownership and non-direct control that
would not reasonably be expected to have a material adverse effect
on the system of internal accounting controls described below in
this Section 2.2(i)(ii). The Company (A) has
implemented and maintains disclosure controls and procedures (as
defined in Rule 13a-15(e) of the Exchange Act) to ensure
that material information relating to the Company, including the
consolidated Company Subsidiaries, is made known to the chief
executive officer and the chief financial officer of the Company by
others within those entities, and (B) has disclosed, based on
its most recent evaluation prior to the Signing Date, to the
Company’s outside auditors and the audit committee of the
Board of Directors (x) any significant deficiencies and
material weaknesses in the design or operation of internal controls
over financial reporting (as defined in Rule 13a-15(f) of
the Exchange Act) that are reasonably likely to adversely affect
the Company’s ability to record, process, summarize and
report financial information and (y) any fraud, whether or not
material, that involves management or other employees who have a
significant role in the Company’s internal controls over
financial reporting.
(j)
No Undisclosed
Liabilities . Neither the
Company nor any of the Company Subsidiaries has any liabilities or
obligations of any nature (absolute, accrued, contingent or
otherwise) which are not properly reflected or reserved against in
the Company Financial Statements to the extent required to be so
reflected or reserved against in accordance with GAAP, except for
(A) liabilities that have arisen since the last fiscal year
end in the ordinary and usual course of business and consistent
with past practice and (B) liabilities that,
9
individually or in the aggregate, have not had
and would not reasonably be expected to have a Company Material
Adverse Effect.
(k)
Offering of Securities . Neither the Company nor any person
acting on its behalf has taken any action (including any offering
of any securities of the Company under circumstances which would
require the integration of such offering with the offering of any
of the Purchased Securities under the Securities Act, and the
rules and regulations of the SEC promulgated thereunder),
which might subject the offering, issuance or sale of any of the
Purchased Securities to Investor pursuant to this Agreement to the
registration requirements of the Securities Act.
(l)
Litigation and Other Proceedings . Except (i) as set
forth on Schedule D or (ii) as would not, individually
or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect, there is no (A) pending or, to the
knowledge of the Company, threatened, claim, action, suit,
investigation or proceeding, against the Company or any Company
Subsidiary or to which any of their assets are subject nor is the
Company or any Company Subsidiary subject to any order, judgment or
decree or (B) unresolved violation, criticism or exception by
any Governmental Entity with respect to any report or relating to
any examinations or inspections of the Company or any Company
Subsidiaries.
(m)
Compliance with Laws. Except as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, the Company and the Company
Subsidiaries have all permits, licenses, franchises,
authorizations, orders and approvals of, and have made all filings,
applications and registrations with, Governmental Entities that are
required in order to permit them to own or lease their properties
and assets and to carry on their business as presently conducted
and that are material to the business of the Company or such
Company Subsidiary. Except as set forth on Schedule E
, the Company and the Company Subsidiaries have complied in all
respects and are not in default or violation of, and none of them
is, to the knowledge of the Company, under investigation with
respect to or, to the knowledge of the Company, have been
threatened to be charged with or given notice of any violation of,
any applicable domestic (federal, state or local) or foreign law,
statute, ordinance, license, rule, regulation, policy or guideline,
order, demand, writ, injunction, decree or judgment of any
Governmental Entity, other than such noncompliance, defaults or
violations that would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.
Except for statutory or regulatory restrictions of general
application or as set forth on Schedule E , no Governmental
Entity has placed any restriction on the business or properties of
the Company or any Company Subsidiary that would, individually or
in the aggregate, reasonably be expected to have a Company Material
Adverse Effect.
(n)
Employee Benefit Matters . Except as would not reasonably be
expected to have, either individually or in the aggregate, a
Company Material Adverse Effect: (A) each “employee
benefit plan” (within the meaning of
Section 3(3) of the Employee Retirement Income Security
Act of 1974, as amended (“ ERISA ”)) providing
benefits to any current or former employee, officer or director of
the Company or any member of its “
Controlled
10
Group ” (defined as any organization which is a
member of a controlled group of corporations within the meaning of
Section 414 of the Internal Revenue Code of 1986, as amended
(the “ Code ”)) that is sponsored, maintained or
contributed to by the Company or any member of its Controlled Group
and for which the Company or any member of its Controlled Group
would have any liability, whether actual or contingent (each, a
“ Plan ”) has been maintained in compliance with
its terms and with the requirements of all applicable statutes,
rules and regulations, including ERISA and the Code;
(B) with respect to each Plan subject to Title IV of ERISA
(including, for purposes of this clause (B), any plan subject to
Title IV of ERISA that the Company or any member of its Controlled
Group previously maintained or contributed to in the six years
prior to the Signing Date), (1) no “reportable
event” (within the meaning of Section 4043(c) of
ERISA), other than a reportable event for which the notice
period referred to in Section 4043(c) of ERISA has been
waived, has occurred in the three years prior to the Signing Date
or is reasonably expected to occur, (2) no “accumulated
funding deficiency” (within the meaning of Section 302
of ERISA or Section 412 of the Code), whether or not waived,
has occurred in the three years prior to the Signing Date or is
reasonably expected to occur, (3) the fair market value of the
assets under each Plan exceeds the present value of all benefits
accrued under such Plan (determined based on the assumptions used
to fund such Plan) and (4) neither the Company nor any member
of its Controlled Group has incurred in the six years prior to the
Signing Date, or reasonably expects to incur, any liability under
Title IV of ERISA (other than contributions to the Plan or premiums
to the PBGC in the ordinary course and without default) in respect
of a Plan (including any Plan that is a “multiemployer
plan”, within the meaning of Section 4001(c)(3) of
ERISA); and (C) each Plan that is intended to be qualified
under Section 401(a) of the Code has received a favorable
determination letter from the Internal Revenue Service with respect
to its qualified status that has not been revoked, or such a
determination letter has been timely applied for but not received
by the Signing Date, and nothing has occurred, whether by action or
by failure to act, which could reasonably be expected to cause the
loss, revocation or denial of such qualified status or favorable
determination letter.
(o)
Taxes . Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect, (i) the Company and the Company Subsidiaries
have filed all federal, state, local and foreign income and
franchise Tax returns required to be filed through the Signing
Date, subject to permitted extensions, and have paid all Taxes due
thereon, and (ii) no Tax deficiency has been determined
adversely to the Company or any of the Company Subsidiaries, nor
does the Company have any knowledge of any Tax deficiencies.
“ Tax ” or “ Taxes ” means
any federal, state, local or foreign income, gross receipts,
property, sales, use, license, excise, franchise, employment,
payroll, withholding, alternative or add on minimum, ad valorem,
transfer or excise tax, or any other tax, custom, duty,
governmental fee or other like assessment or charge of any kind
whatsoever, together with any interest or penalty, imposed by any
Governmental Entity.
(p)
Properties and Leases . Except as would not, individually or
in the aggregate, reasonably be expected to have a Company Material
Adverse Effect, the Company and the Company Subsidiaries have good
and marketable title to all real properties and all other
properties and assets owned by them, in each case free from liens,
encumbrances, claims and
11
defects that would affect the value thereof or
interfere with the use made or to be made thereof by them.
Except as would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect, the Company
and the Company Subsidiaries hold all leased real or personal
property under valid and enforceable leases with no exceptions that
would interfere with the use made or to be made thereof by
them.
(q)
Environmental
Liability . Except as
would not, individually or in the aggregate, reasonably be expected
to have a Company Material Adverse Effect:
(i)
there is no legal, administrative,
or other proceeding, claim or action of any nature seeking to
impose, or that would reasonably be expected to result in the
imposition of, on the Company or any Company Subsidiary, any
liability relating to the release of hazardous substances as
defined under any local, state or federal environmental statute,
regulation or ordinance, including the Comprehensive Environmental
Response, Compensation and Liability Act of 1980, pending or, to
the Company’s knowledge, threatened against the Company or
any Company Subsidiary;
(ii)
to the Company’s knowledge,
there is no reasonable basis for any such proceeding, claim or
action; and
(iii)
neither the Company nor any Company
Subsidiary is subject to any agreement, order, judgment or decree
by or with any court, Governmental Entity or third party imposing
any such environmental liability.
(r)
Risk Management
Instruments . Except as
would not, individually or in the aggregate, reasonably be expected
to have a Company Material Adverse Effect, all derivative
instruments, including, swaps, caps, floors and option agreements,
whether entered into for the Company’s own account, or for
the account of one or more of the Company Subsidiaries or its or
their customers, were entered into (i) only in the ordinary
course of business, (ii) in accordance with prudent practices
and in all material respects with all applicable laws, rules,
regulations and regulatory policies and (iii) with
counterparties believed to be financially responsible at the time;
and each of such instruments constitutes the valid and legally
binding obligation of the Company or one of the Company
Subsidiaries, enforceable in accordance with its terms, except as
may be limited by the Bankruptcy Exceptions. Neither the
Company or the Company Subsidiaries, nor, to the knowledge of the
Company, any other party thereto, is in breach of any of its
obligations under any such agreement or arrangement other than such
breaches that would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse
Effect.
(s)
Agreements with Regulatory
Agencies . Except as set
forth on Schedule F , neither the Company nor any Company
Subsidiary is subject to any material cease-and-desist or other
similar order or enforcement action issued by, or is a party to any
material written agreement, consent agreement or memorandum of
understanding with, or is a party to any commitment letter or
similar undertaking to, or is subject to any capital directive by,
or since December 31, 2006, has adopted any board resolutions
at the request of, any Governmental
12
Entity (other than the Appropriate Federal
Banking Agencies with jurisdiction over the Company and the Company
Subsidiaries) that currently restricts in any material respect the
conduct of its business or that in any material manner relates to
its capital adequacy, its liquidity and funding policies and
practices, its ability to pay dividends, its credit, risk
management or compliance policies or procedures, its internal
controls, its management or its operations or business (each item
in this sentence, a “ Regulatory Agreement ”),
nor has the Company or any Company Subsidiary been advised since
December 31, 2006 by any such Governmental Entity that it is
considering issuing, initiating, ordering, or requesting any such
Regulatory Agreement. The Company and each Company Subsidiary
are in compliance in all material respects with each Regulatory
Agreement to which it is party or subject, and neither the Company
nor any Company Subsidiary has received any notice from any
Governmental Entity indicating that either the Company or any
Company Subsidiary is not in compliance in all material respects
with any such Regulatory Agreement. “ Appropriate
Federal Banking Agency ” means the “appropriate
Federal banking agency” with respect to the Company or such
Company Subsidiaries, as applicable, as defined in
Section 3(q) of the Federal Deposit Insurance Act (12
U.S.C. Section 1813(q)).
(t)
Insurance . The Company and the Company Subsidiaries are
insured with reputable insurers against such risks and in such
amounts as the management of the Company reasonably has determined
to be prudent and consistent with industry practice. The
Company and the Company Subsidiaries are in material compliance
with their insurance policies and are not in default under any of
the material terms thereof, each such policy is outstanding and in
full force and effect, all premiums and other payments due under
any material policy have been paid, and all claims thereunder have
been filed in due and timely fashion, except, in each case, as
would not, individually or in the aggregate, reasonably be expected
to have a Company Material Adverse Effect.
(u)
Intellectual Property
. Except as would not, individually
or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect, (i) the Company and each Company
Subsidiary owns or otherwise has the right to use, all intellectual
property rights, including all trademarks, trade dress, trade
names, service marks, domain names, patents, inventions, trade
secrets, know-how, works of authorship and copyrights therein, that
are used in the conduct of their existing businesses and all rights
relating to the plans, design and specifications of any of its
branch facilities (“ Proprietary Rights ”) free
and clear of all liens and any claims of ownership by current or
former employees, contractors, designers or others and
(ii) neither the Company nor any of the Company Subsidiaries
is materially infringing, diluting, misappropriating or violating,
nor has the Company or any or the Company Subsidiaries received any
written (or, to the knowledge of the Company, oral) communications
alleging that any of them has materially infringed, diluted,
misappropriated or violated, any of the Proprietary Rights owned by
any other person. Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect, to the Company’s knowledge, no other person
is infringing, diluting, misappropriating or violating, nor has the
Company or any or the Company Subsidiaries sent any written
communications since January 1, 2006 alleging that any person
has infringed, diluted, misappropriated or violated, any of the
Proprietary Rights owned by the Company and the Company
Subsidiaries.
13
(v)
Brokers and Finders
. No broker, finder or investment
banker is entitled to any financial advisory, brokerage,
finder’s or other fee or commission in connection with this
Agreement or the Warrant or the transactions contemplated hereby or
thereby based upon arrangements made by or on behalf of the Company
or any Company Subsidiary for which the Investor could have any
liability.
14
Article III
Covenants
3.1
Commercially Reasonable
Efforts .
(a)
Subject to the terms and conditions
of this Agreement, each of the parties will use its commercially
reasonable efforts in good faith to take, or cause to be taken, all
actions, and to do, or cause to be done, all things necessary,
proper or desirable, or advisable under applicable laws, so as to
permit consummation of the Purchase as promptly as practicable and
otherwise to enable consummation of the transactions contemplated
hereby and shall use commercially reasonable efforts to cooperate
with the other party to that end.
(b)
If the Company is required to obtain
any stockholder approvals set forth on Schedule C , then the
Company shall comply with this Section 3.1(b) and
Section 3.1(c). The Company shall call a special meeting of
its stockholders, as promptly as practicable following the Closing,
to vote on proposals (collectively, the “ Stockholder
Proposals ”) to (i) approve the exercise of the
Warrant for Common Stock for purposes of the rules of the
national security exchange on which the Common Stock is listed
and/or (ii) amend the Company’s Charter to increase the
number of authorized shares of Common Stock to at least such number
as shall be sufficient to permit the full exercise of the Warrant
for Common Stock and comply with the other provisions of this
Section 3.1(b) and Section 3.1(c). The Board of
Directors shall recommend to the Company’s stockholders that
such stockholders vote in favor of the Stockholder Proposals. In
connection with such meeting, the Company shall prepare (and the
Investor will reasonably cooperate with the Company to prepare) and
file with the SEC as promptly as practicable (but in no event more
than ten business days after the Closing) a preliminary proxy
statement, shall use its reasonable best efforts to respond to any
comments of the SEC or its staff thereon and to cause a definitive
proxy statement related to such stockholders’ meeting to be
mailed to the Company’s stockholders not more than five
business days after clearance thereof by the SEC, and shall use its
reasonable best efforts to solicit proxies for such stockholder
approval of the Stockholder Proposals. The Company shall
notify the Investor promptly of the receipt of any comments from
the SEC or its staff w